The combined service portfolio of Pharmatest provides an unparalleled selection of efficacy and safety models for preclinical drug discovery in disease areas with only a few service providers available. With the merger, Pharmatest will solidify its position as a global provider of preclinical research services.

Previously Pharmatest has focused on bone biology and pharmacodynamic models of musculoskeletal diseases and cancer-induced bone disease. Genolyze’s core competence is in the design and implementation of bioinformatics and database solutions tailored specifically with pharmaceutical industry in mind. Orthotopix is specialised in orthotopic cancer models (prostate and pancreatic) and disease models of lower urinary tract disorders and infections. Orthotopix also offers certain safety models designed in compliance with the guidelines for REACH program, allowing the testing of various products and substances for possible hormonal interactions as mandated in the European Community Regulations.

Pharmatest has over a decade of expertise in bone biology and the company has already achieved an internationally recognised status as one of the world’s leading service providers in its market niche. “This merger opens up new opportunities in a much larger sector of drug discovery. In the pharmaceutical industry and preclinical research in particular, outsourcing is a continuously increasing trend. Companies developing new therapies have a growing need for highly predictive preclinical models that will reduce attrition in clinical phases of drug development. We strongly believe that there is a great demand for a company who specialises in translational research and customised service that is tailor-made for each customer. Our future in the new market looks promising”, said Pharmatest’s CEO Jussi Halleen.